Gaudium IVF launches AI powered Signature Labs; kicks off 19 centre expansion

Gaudium IVF and Women Health Limited, India’s first publicly listed IVF chain, kicked off its first milestone in the company’s planned 19-centre expansion, as outlined in the growth roadmap shared with investors during its IPO. The launch reinforces the company’s commitment to making high quality, technology driven fertility care more accessible to aspiring parents through a standardised clinical and laboratory model that combines AI powered innovation with the highest standards of clinical excellence, patient safety and ethical care.

Strategically located in South Delhi, the new centre offers comprehensive fertility care under one roof, combining experienced fertility specialists, advanced reproductive medicine and Gaudium IVF’s standardised clinical protocols. At the heart of the new centre is the Gaudium Signature Lab, the company’s proprietary laboratory framework that integrates advanced embryology, AI-powered technologies and internationally benchmarked quality standards to create an optimal environment for embryo development.

As Gaudium IVF expands its network, the Signature Lab model will be replicated across every new centre, ensuring patients experience the same high standards of precision, safety and clinical excellence, irrespective of location. The centre also brings together Gaudium IVF’s AI-powered embryology ecosystem, including SiD (Sperm Identification Device) for advanced sperm assessment and ERICA (Embryo Ranking Intelligent Classification Assistant) for embryo evaluation. By complementing the expertise of embryologists with data-driven insights, these technologies enhance precision, consistency and confidence throughout the IVF journey.

Commenting on the launch, Dr. Manika Khanna, chairperson and managing director, Gaudium IVF, said: “Fertility care is one of the most specialised fields of medicine, where science, clinical expertise and ethical practices come together to help couples realise their dream of parenthood. At Gaudium IVF, we believe every patient deserves care that is not only clinically advanced but also transparent, compassionate and centred around their individual needs.”

Through its planned network expansion, Gaudium IVF aims to replicate its Signature Lab model across new centres, combining advanced reproductive medicine, AI-powered embryology and standardised clinical protocols to deliver consistent, high-quality fertility care at scale and reinforce its leadership in India’s rapidly evolving fertility care sector.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre